Fig. 2From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trialSurvival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b). Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE not evaluableBack to article page